- Home
- ALTO vs ABOS Comparison
ALTO vs ABOS Comparison
Compare ALTO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALTO | ABOS |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 155.7M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALTO | ABOS |
|---|---|---|
| Price | $2.28 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.50 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 629.3K | 350.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $965,258,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $0.86 |
| 52 Week High | $3.18 | $3.05 |
Technical Indicators
Market Signals| Indicator | ALTO | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 69.85 |
| Support Level | $0.99 | $1.17 |
| Resistance Level | $2.91 | N/A |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 4.07 | 87.00 |
Price Performance
Historical ComparisonAbout ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under four segments: Marketing and distribution, Pekin Campus production, Western production, and Corporate.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.